Note: This document is an English translation of a statement written originally in Japanese. The Japanese original should be considered as the primary version.

November 16, 2026

Company name: Zeria Pharmaceutical Co., Ltd.
Name of representative: Mitsuhiro Ibe,
Representative Director, President
(Securities code: 4559; Prime Market, TSE)
Inquiries: Koichi Tamura
Director, Public Relations Division
(Telephone: +81-3-3661-1039)

(Correction) Partial Correction to "Notice Concerning Acquisition of Equity Interests of Haupt Pharma Wülfling GmbH (Making It a Sub-subsidiary) by a Consolidated Subsidiary" and "Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2027 (Under Japanese GAAP)"

Zeria Pharmaceutical Co., Ltd. hereby announces that there were errors in a portion of the descriptions in the "Notice Concerning Acquisition of Equity Interests of Haupt Pharma Wülfling GmbH (Making It a Sub-subsidiary) by a Consolidated Subsidiary" disclosed on October 26, 2026, and the "Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2027 (Under Japanese GAAP)" disclosed on November 4, 2026, and corrects them as follows. Please note that there are no corrections to the numerical data.

1. Reason for the Correction

Because there was an error in the trade name (alphabetical spelling) of the target company of the acquisition of equity interests, the relevant sections in each disclosure document are being corrected.

2. Details of the Correction (The corrected parts are underlined.)

(1) Corrections to the "Notice Concerning Acquisition of Equity Interests of Haupt Pharma Wülfling GmbH (Making It a Sub-subsidiary) by a Consolidated Subsidiary"

[Title]

(Before correction)

Notice Concerning Acquisition of Equity Interests of Haupt Pharma <u>Wülfling</u> GmbH (Making It a Sub-subsidiary) by a Consolidated Subsidiary

(After correction)

Notice Concerning Acquisition of Equity Interests of Haupt Pharma <u>Wülfing</u> GmbH (Making It a Sub-subsidiary) by a Consolidated Subsidiary

[Opening paragraph (Preamble)]

(Before correction)

Zeria Pharmaceutical Co., Ltd. (the "Company") hereby announces that its Swiss consolidated subsidiary, Tillotts Pharma AG ("Tillotts"), entered into an equity interest purchase agreement on October 23, 2026 (Swiss time), to acquire all equity interests of Haupt Pharma <u>Wülfling</u> GmbH ("HPW") from Aenova Holding GmbH ("Aenova").

(After correction)

Zeria Pharmaceutical Co., Ltd. (the "Company") hereby announces that its Swiss consolidated

subsidiary, Tillotts Pharma AG ("Tillotts"), entered into an equity interest purchase agreement on October 23, 2026 (Swiss time), to acquire all equity interests of Haupt Pharma Wülfing GmbH ("HPW") from Aenova Holding GmbH ("Aenova").

[3. Overview of the sub-subsidiary to be acquired (HPW)]
(1) Name
(Before correction)
Haupt Pharma Wülfling GmbH

(After correction)
Haupt Pharma Wülfing GmbH

(2) Corrections to the "Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2027 (Under Japanese GAAP)"
[Attached Material Page 11]
(Before correction)
(Notes on significant subsequent events)
Business combination by acquisition
Tillotts Pharma AG, the Company's Swiss consolidated subsidiary, entered into an equity interest purchase agreement on October 23, 2026 (Swiss time) to acquire all equity interests of Haupt Pharma Wülfling GmbH from Aenova Holding GmbH.
For more details, please see the Notice Concerning Acquisition of Equity Interests of Haupt Pharma Wülfling GmbH (Making It a Sub-subsidiary) by a Consolidated Subsidiary announced on October 26, 2026.

(After correction)
Business combination by acquisition
Tillotts Pharma AG, the Company's Swiss consolidated subsidiary, entered into an equity interest purchase agreement on October 23, 2026 (Swiss time) to acquire all equity interests of Haupt Pharma Wülfing GmbH from Aenova Holding GmbH.
For more details, please see the Notice Concerning Acquisition of Equity Interests of Haupt Pharma Wülfing GmbH (Making It a Sub-subsidiary) by a Consolidated Subsidiary announced on October 26, 2026.